Assaf Segal is the Chief Executive Officer at Clal Biotechnology Industries Ltd. (TASE:CBI) and is the managing partner of Anatomy Medical Technology Funds. Assaf serves as a Board Member of several companies, including MediWound Ltd. (Nasdaq: MDWD), eXIthera Pharmaceuticals, FDNA Inc., Biokine therapeutics Ltd. and Colospan Ltd. Prior to that, Mr. Segal served as the CFO of CBI, founded and was a partner at Variance Financials Ltd., held a managerial position at PwC Advisory and was an Economic Department manager at Amdocs Inc. (NYSE: DOX).
Mr. Segal holds an MBA in Finance and a B.A. in Economics and Statistics from the Hebrew University of Jerusalem.